An FDA advisory panel just recommended yesterday that the warning label for Covidien’s Optimark and GE’s Omnisca—drugs in the family of medications known as gadolinium-based contrast agents (DBCAs)—be updated to restrict their use in patients with severe kidney disease because of the potential for an increased risk of nephrogenic systemic fibrosis (NSF). NSF causes thickening of the skin and organs. GBCAs carry a strong “black box” warning. This site has good information on this issue: http://www.gadolinium-mri.com/index.html